- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...
BRIDGEWATER, N.J., January 23, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has ...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic ...
It is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets in the US market Dr Reddy’s Laboratories has launched memantine hydrochloride tablets USP, 5 mg and 10 mg, a ...
According to Business Research Insights the Memantine Hydrochloride Tablets Market expected to exhibit a CAGR of 5.9% by 2033. The "Memantine Hydrochloride Tablets Market" Research is your essential ...
The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...
Actavis and Adamas Pharmaceuticals Inc announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine ...
Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results